SCHEMBL3924707

SCHEMBL3924707

CN(c1cc(-c2ccccc2)c2ncn(C)c2c1)c1ccnc(NCCc2cccnc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 4/20 0.45
▸ MKNK2 Q9HBH9 4/20 0.45
▸ OGA O60502 2/20 0.41
▸ ADRA2B P18089 1/20 0.37
▸ ADRA2C P18825 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ HRH2 P25021 1/20 0.37
▸ HTR1D P28221 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ HTR7 P34969 1/20 0.37
▸ HTR2B P41595 1/20 0.37
▸ HTR5A P47898 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ TMEM97 Q5BJF2 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ HRH4 Q9H3N8 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ CCNA2 P20248 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3927808 0.85 NPC1 (0.36) MKNK1MKNK2ADRA2BADRA2CSLC6A2
SCHEMBL3924418 0.84 OGA (0.40) MKNK1MKNK2OGACCNA2CDK2
SCHEMBL3935077 0.83 MAP3K5 (0.41) MKNK1MKNK2HTR7CCNA2CDK2
SCHEMBL3924760 0.82 HRH4 (0.43) HRH4CCNA2CDK2CCNA1CCNT1
SCHEMBL3924645 0.78 CCNE2 (0.45) HRH4CCNA2CDK2CCNA1CCNE2
SCHEMBL5914124 0.77 OGA (0.48) MKNK1MKNK2OGAADRA2BADRA2C
SCHEMBL3922932 0.76 KDR (0.39) CCNA2CDK2CCNA1CDK1CDK5
SCHEMBL3927419 0.76 KDR (0.33) CCNA2CDK2CCNA1CYP3A4CYP2D6
SCHEMBL5914120 0.76 HTR7 (0.44) MKNK1MKNK2OGAADRA2BADRA2C
SCHEMBL3926763 0.75 DPP4 (0.36) CCNA2CDK2CCNA1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP claimed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO claimed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US claimed
EP-2041118-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen, Inc (US) 2009-04-01 — — EP disclosed
WO-2007114827-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2007-10-11 — — WO disclosed
US-20060247263-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247263-A1 Substituted heterocyclic compounds and methods of use MAPT, IAPP, MYLK2 MKNK1 854/4885MKNK2 874/4885OGA 3178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback